I-Kappa-B Kinase Epsilon (CT) (IKKε) Blocking Peptide

I-Kappa-B Kinase Epsilon (CT) (IKKε) Blocking Peptide

Product No.: I-472

[product_table name="All Top" skus="I-472"]

- -
- -
Target
I-Kappa-B Kinase Epsilon (CT)
Product Type
Blocking Peptide
Alternate Names
IKKi, IKKepsilon

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Amino Acid Location
This peptide sequence is located at amino acids 701 to 716 of Human IKKε protein.
Formulation
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Amino Acid Sequence
16 amino acids near the carboxy terminus of human IKK epsilon.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Background
I-Kappa-B Kinase Epsilon (CT) peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

Antigen Details

References & Citations

1. Pan G; O'Rourke K; Chinnaiyan et al.. The receptor for the cytotoxic ligand TRAIL. Science; 1997;276:111-113 2. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8 3. Sheridan JP, Marsters SA, Pitti RM, et al. A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21 4. Degli-Esposti MA, Smolak PJ, Walczak H, et al, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186(7):1165-70
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.